依折麦布联合他汀类药物对冠心病患者血脂代谢及心功能指标的影响
|
摘要
目的观察依折麦布联合他汀类药物对冠心病患者血脂代谢及心功能指标的影响。方法选取118例冠心病患者为研究对象,按照随机数表法分为观察组和对照组,各59例。2组均进行常规治疗,对照组予以他汀类药物治疗,观察组在对照组基础上联合依折麦布治疗。比较2组治疗效果、血脂代谢、心功能指标及不良反应。结果观察组治疗总有效率91.53%,高于对照组76.27%,差异有统计学意义(P<0.05)。对照组治疗后总胆固醇(TC)为(4.13±0.56)mmol/L,高于观察组的(3.24±0.26) mmol/L;低密度脂蛋白胆固醇(LDL-C)为(1.32±0.16)mmol/L,低于观察组的(2.43±0.92)mmol/L;三酰甘油(TG)为(3.24±0.15)mmol/L,高于观察组的(2.25±0.62)mmol/L;高密度脂蛋白胆固醇(HDL-C)为(1.32±0.16)mmol/L,低于观察组的(1.46±0.41)mmol/L,差异有统计学意义(P<0.05)。对照组治疗后左心室收缩末期内径(LVESD)为(34.58±2.34)mm,高于观察组的(31.32±2.05)mm;对照组左心室舒张末期内径(LVEDD)为(59.17±3.52)mm,高于观察组的(53.67±3.35)mm;对照组左心室射血分数(LVEF)为(54.39±3.27)%,低于观察组的(59.62±2.74)%,差异有统计学意义(P<0.05)。2组治疗期间均无明显不良反应。结论依折麦布联合他汀类药物治疗冠心病效果较好,可有效调节血脂水平,改善心功能。
To observe the effect of Ezetimibe combined with statins on blood lipid metabolism and cardiac function indexes in patients with coronary heart disease(CHD). Methods 118 CHD patients were divided into two groups by random number table, 59 cases in each group.Two groups were given symptomatic treatment. The control group was given statins, while the observation group was treated with Ezetimibe based on control group.The curative effects, blood lipid metabolism, cardiac function indexes and adverse reactions were compared between the two groups. Results The total effective rate of the observation group(91.53%) and the control group(76.27%) were compared, and there was statistical difference(P<0.05). After treatment, the levels of TC, LDL-C, TG in the control group were [(4.13±0.56)mmol/L,(1.32±0.16)mmol/L,(3.24±0.15)mmol/L] and the observation group [(3.24±0.26)mmol/L,(2.43±0.92)mmol/L,(2.25±0.62)mmol/L] were compared. There was statistical difference(P<0.05). The level of HDL-C in the control group [(1.32±0.16)mmol/L] was lower than the observation group [(1.46±0.41)mmol/L](P<0.05). After treatment, the LVESD and LVEDD in control group were[(34.58±2.34)mm,(59.17±3.52)mm] and observation group [(31.32±2.05)mm,(53.67±3.35)mm], and there was statistical difference(P<0.05). The LVEF in the control group [(54.39±3.27)%] was lower than the observation group [(59.62±2.74)%](P<0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion Ezetimibe combined with statins in treatment of CHD is effective. It can regulate blood lipid level and improve cardiac function, which is safe and reliable.
To observe the effect of Ezetimibe combined with statins on blood lipid metabolism and cardiac function indexes in patients with coronary heart disease(CHD). Methods 118 CHD patients were divided into two groups by random number table, 59 cases in each group.Two groups were given symptomatic treatment. The control group was given statins, while the observation group was treated with Ezetimibe based on control group.The curative effects, blood lipid metabolism, cardiac function indexes and adverse reactions were compared between the two groups. Results The total effective rate of the observation group(91.53%) and the control group(76.27%) were compared, and there was statistical difference(P<0.05). After treatment, the levels of TC, LDL-C, TG in the control group were [(4.13±0.56)mmol/L,(1.32±0.16)mmol/L,(3.24±0.15)mmol/L] and the observation group [(3.24±0.26)mmol/L,(2.43±0.92)mmol/L,(2.25±0.62)mmol/L] were compared. There was statistical difference(P<0.05). The level of HDL-C in the control group [(1.32±0.16)mmol/L] was lower than the observation group [(1.46±0.41)mmol/L](P<0.05). After treatment, the LVESD and LVEDD in control group were[(34.58±2.34)mm,(59.17±3.52)mm] and observation group [(31.32±2.05)mm,(53.67±3.35)mm], and there was statistical difference(P<0.05). The LVEF in the control group [(54.39±3.27)%] was lower than the observation group [(59.62±2.74)%](P<0.05). There were no obvious adverse reactions in the two groups during treatment. Conclusion Ezetimibe combined with statins in treatment of CHD is effective. It can regulate blood lipid level and improve cardiac function, which is safe and reliable.
引文
[1] 汪玉君,宋巧凤,王希柱,等.依折麦布联合他汀类药物对冠心病患者的调脂及抗炎作用[J].宁夏医科大学学报,2015,37(10):1227-1229.
[2] 徐春华,苏慧,王晓明.依折麦布在老年冠心病合并高脂血症患者中的应用[J].中华保健医学杂志,2014,16(3):223-224.
[3] 郑虹,米树华,张涛,等.瑞舒伐他汀联合依折麦布调脂治疗对冠状动脉粥样硬化性心脏病患者胆固醇代谢标志物的影响[J].中国医药,2016,11(9):1265-1269.
[4] 左国兴,王蹿蹿,杜新平,等.依折麦布联合辛伐他汀在冠心病调脂治疗未达标患者中的效果观察[J].中国医院药学杂志,2014,34(16):1385-1388.
[5] 黄珊,李天发,李巍景,等.辛伐他汀联合依折麦布对冠心病患者的作用机制研究[J].中国临床药理学杂志,2015,31(19):1901-1903.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):263-279.
[7] 贾媛芳,张雪娟,郭俊杰.依折麦布与他汀类药物联合降脂治疗及其多效性研究进展[J].岭南心血管病杂志,2015,21(3):442-444.
[8] 苑小历,胡文星,张凯,等.依折麦布联合舒洛地特对高龄冠心病患者血脂和TNF-α、IL-6水平的影响[J].江苏医药,2014,40(7):800-802.
[9] 黄寰,何晓青,张慧敏,等.依折麦布对冠心病调脂不佳患者脂糖代谢及肝肾功能的影响[J].热带医学杂志,2017,17(1):89-92.
[10] 王爽,郑秀艳,孙文华,等.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].现代生物医学进展,2017,17(13):2470-2473.
[11] 刘杰,薛浩,耿晓雯,等.依折麦布联合阿托伐他汀类对低密度脂蛋白胆固醇未达标的急性冠脉综合征患者胆固醇代谢的影响[J].解放军医学院学报,2017,38(8):62-63.
[12] 周芳,辛庆锋.依折麦布调脂对冠心病患者血脂和颈动脉粥样硬化斑块的疗效[J].心血管康复医学杂志,2016,25(3):296-299.
[13] 王粉鱼.阿托伐他汀钙联合依折麦布对冠心病的疗效及安全性[J].山西医药杂志,2017,46(12):1465-1467.
[14] 李荣,郑义,肖艳平.阿托伐他汀钙联合依折麦布药物对冠心病治疗效果与临床安全性评价[J].心肺血管病杂志,2016,35(4):266-268.
[15] 丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044.
[2] 徐春华,苏慧,王晓明.依折麦布在老年冠心病合并高脂血症患者中的应用[J].中华保健医学杂志,2014,16(3):223-224.
[3] 郑虹,米树华,张涛,等.瑞舒伐他汀联合依折麦布调脂治疗对冠状动脉粥样硬化性心脏病患者胆固醇代谢标志物的影响[J].中国医药,2016,11(9):1265-1269.
[4] 左国兴,王蹿蹿,杜新平,等.依折麦布联合辛伐他汀在冠心病调脂治疗未达标患者中的效果观察[J].中国医院药学杂志,2014,34(16):1385-1388.
[5] 黄珊,李天发,李巍景,等.辛伐他汀联合依折麦布对冠心病患者的作用机制研究[J].中国临床药理学杂志,2015,31(19):1901-1903.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):263-279.
[7] 贾媛芳,张雪娟,郭俊杰.依折麦布与他汀类药物联合降脂治疗及其多效性研究进展[J].岭南心血管病杂志,2015,21(3):442-444.
[8] 苑小历,胡文星,张凯,等.依折麦布联合舒洛地特对高龄冠心病患者血脂和TNF-α、IL-6水平的影响[J].江苏医药,2014,40(7):800-802.
[9] 黄寰,何晓青,张慧敏,等.依折麦布对冠心病调脂不佳患者脂糖代谢及肝肾功能的影响[J].热带医学杂志,2017,17(1):89-92.
[10] 王爽,郑秀艳,孙文华,等.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].现代生物医学进展,2017,17(13):2470-2473.
[11] 刘杰,薛浩,耿晓雯,等.依折麦布联合阿托伐他汀类对低密度脂蛋白胆固醇未达标的急性冠脉综合征患者胆固醇代谢的影响[J].解放军医学院学报,2017,38(8):62-63.
[12] 周芳,辛庆锋.依折麦布调脂对冠心病患者血脂和颈动脉粥样硬化斑块的疗效[J].心血管康复医学杂志,2016,25(3):296-299.
[13] 王粉鱼.阿托伐他汀钙联合依折麦布对冠心病的疗效及安全性[J].山西医药杂志,2017,46(12):1465-1467.
[14] 李荣,郑义,肖艳平.阿托伐他汀钙联合依折麦布药物对冠心病治疗效果与临床安全性评价[J].心肺血管病杂志,2016,35(4):266-268.
[15] 丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044.